PFG
INSY

Piershale Financial Group’s Insys Therapeutics, Inc. INSY Stock Holding History

Piershale Financial Group’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-150
Closed -$3K – 178
2014
Q3 		$3K Buy
150
+50
+50% +$785 ﹤0.01% 116
2014
Q2 		$2K Buy
+100
New +$1.62K ﹤0.01% 136

Other funds holding INSY

JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Piershale Financial Group's INSY Position: Q4 2014 in Review

Piershale Financial Group sold out of Insys Therapeutics, Inc. (INSY) in Q4 2014, closing a stake of 150 shares — an estimated $3K sold.

Piershale Financial Group first reported a position in INSY in Q2 2014 and held it in 2 quarters. The position peaked at $3K in Q3 2014. 113 funds tracked by Wall St. Rank hold INSY as of Q4 2014.

  • Piershale Financial Group reported no remaining Insys Therapeutics, Inc. position as of Q4 2014 after selling out during the quarter.
  • Piershale Financial Group sold 150 Insys Therapeutics, Inc. shares in Q4 2014, an estimated $3K.
  • Piershale Financial Group first reported a position in Insys Therapeutics, Inc. in Q2 2014 and held it in 2 quarters.
  • Piershale Financial Group's Insys Therapeutics, Inc. position peaked at $3K in Q3 2014.
  • 113 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q4 2014.

Based on Piershale Financial Group's 13F filing for Q4 2014, filed 15 Jan 2015.